Vigil Neuroscience Inc VIGL.OQ VIGL.O is expected to show no change in quarterly revenue when it reports results on August 1 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Vigil Neuroscience Inc is for a loss of 42 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vigil Neuroscience Inc is $8.00, about 0.8% below its last closing price of $8.06
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.52 | -0.53 | -0.49 | Beat | 7.6 |
Dec. 31 2025 | -0.55 | -0.53 | -0.57 | Missed | -7.8 |
Sep. 30 2024 | -0.53 | -0.54 | -0.47 | Beat | 13.7 |
Jun. 30 2024 | -0.54 | -0.55 | -0.52 | Beat | 5.5 |
Mar. 31 2024 | -0.60 | -0.61 | -0.50 | Beat | 17.5 |
Dec. 31 2023 | -0.61 | -0.53 | -0.57 | Missed | -6.7 |
Sep. 30 2023 | -0.58 | -0.57 | -0.53 | Beat | 7.5 |
Jun. 30 2023 | -0.56 | -0.54 | -0.52 | Beat | 4.2 |
This summary was machine generated July 30 at 13:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments